SLC22A17 and cardiomyopathy: Variants SLC22A17-rs4982753 and SLC22A7-rs4149178 were associated with decreasing risk of cardiomyopathy in Canadian CCS (p = 0.0078 and 0.0034, respectively) and were validated in a replication cohort (p = 0.0071 and 0.047, respectively).